MK-2206 is a highly selective allosteric inhibitor of AKT currently in phase II studies for patients with refractory renal cell carcinoma [40], relapsed or refractory lymphoma [41], and advanced thoracic malignancies [42]. This evidence concerns the gene AKT1 and lymphoma.